Leptin and adiponectin as predictors of disease activity in rheumatoid arthritis.

Autor:	Xibillé-Friedmann DX; Hospital General de Cuernavaca, SSM/Facultad de Farmacia, UAEM, Morelos, Cuernavaca, Mexico., Ortiz-Panozo E; Center for Population Health Research, Instituto Nacional de Salud Pública, Cuernavaca, Mexico., Bustos Rivera-Bahena C; Facultad de Farmacia, UAEM /Facultad de Ciencias, UAEM, Morelos, Cuernavaca, Mexico., Sandoval-Ríos M; Facultad de Farmacia, UAEM /Facultad de Ciencias, UAEM, Morelos, Cuernavaca; and Depto. de Ciencias y Matemáticas, Centro Regional de Formación Docente e Investigación Educativa del Estado de Sonora, Mexico., Hernández-Góngora SE; Universidad Latinoamericana, School of Medicine, Morelos, Cuernavaca, Mexico., Dominguez-Hernandez L; Universidad Latinoamericana, School of Medicine, Morelos, Cuernavaca, Mexico., Montiel-Hernández JL; Facultad de Farmacia, UAEM /Facultad de Ciencias, UAEM, Morelos, Cuernavaca, Mexico.
Jazyk:	angličtina
Zdroj:	Clinical and experimental rheumatology [Clin Exp Rheumatol] 2015 Jul-Aug; Vol. 33 (4), pp. 471-7. Date of Electronic Publication: 2015 May 01.
Abstrakt:	Objectives: To assess whether baseline levels of leptin and adiponectin predict disease activity or response to treatment in patients with RA at 6 months, 1 and 2 years of follow-up. Methods: A consecutive cohort of patients, classified according to the 2010 ACR/EULAR RA criteria, was evaluated at baseline, 6 months, 1 and 2 years. All were treated with steroids and/or DMARDs. None received biologics. Blood was taken at a baseline to determine plasma anti-CCP, leptin and adiponectin. The relationship between leptin, adiponectin, DAS28 and changes in DAS28 was assessed by multivariable linear and logistic regression from baseline to follow-up. Results: 127 patients completed 6 months, 91 one year and 52 two years of follow-up. All were female, mean age 45 years (18-70), time since onset of disease 7.5 years (0-36). A U-shaped relationship between DAS28 and leptin baseline levels was seen. Adjusting for different factors, leptin levels at baseline predicted higher DAS28 at 6 months and, in patients who were not overweight or obese, predicted disease activity at 6 months, 1 and 2 years. In patients who were not overweight or obese, baseline leptin was able to predict response to treatment at 6 and 12 months. Conclusions: In the short term, baseline leptin levels predict disease activity in all RA patients and response to treatment in RA patients with normal weight.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu